Pancreaticoduodenectomy patients
Conditions
Interventions
Test group:Esketamine 1.5mg/kg + Sufentanil 2ug/kg
Control group:Sufentanil 2ug/kg
Sponsors
Tianjin Medical University Cancer Institute & Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-65 years old, gender is not limited; 2) ASA I-III grade; 3) Patients who plan to undergo elective pancreaticoduodenectomy; 4) No other surgical contraindications; 5) Clearly understand and voluntarily participate in the research, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Receive opioid analgesia before surgery; 2) Drug use, alcohol abuse and drug abusers; 3) Those with preoperative cognitive impairment determined by the MMSE scale (the normal cut-off standard is: >23 points); 4) Have a history of severe cerebrovascular disease; 5) Those with mental illness; 6) Those who refuse to sign informed consent and do not cooperate with the operation; 7) Those who are sensitive to esketamine and related drugs; 8) Patients with severe refractory hypertension, cor pulmonale, hyperthyroidism, epilepsy, increased intraocular pressure, increased intracranial pressure or intracranial space-occupying lesions, history of cerebrovascular accident and other contraindications to the use of ketamine; 9) The investigators believe that patients should not participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HAMD-17 score;RASS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS score;Sufentanil and Esketamine Dosages;PCIA usage;adverse event; | — |
Countries
China
Contacts
Public ContactYiqing Yin
Tianjin Medical University Cancer Institute & Hospital
Outcome results
None listed